Figure 2. Preferential targeting of CD11c⁺ cells at high-dose gp96.

(a,b) Mice were immunized intradermally with low-dose (LD) or high-dose (HD) gp96 or given PBS. After 18 h, draining lymph node (a) and spleens (b) were harvested and absolute numbers of CD11b⁺ and CD11c⁺ populations were analysed. n=5/group, data are from one representative experiment of three independent experiments performed. (c–e) Mice were immunized with low-dose (LD) or high-dose (HD) gp96_A488. Lymph nodes were harvested 8 h later. Lymph node cells were analysed for A488 positivity by flow cytometry using CD11b and CD11c cell surface markers. Each population is shown as a percentage of the total lymph node cells (c). (d) The percent of pDCs in the CD11b⁻CD11c⁺ population from (c) that are A488⁺ is shown as a fraction of total lymph node cells. (e) The percent of pDCs that are A488⁺ is shown. Data are from one representative experiment of three independent experiments. (f) Histograms depict CD91 staining within representative lymph node cDC (CD11b⁺CD11c⁺) or pDC (CD11c^low/+CD11b⁻ B220⁺PDCA1⁺) populations from naive CD91^f/f or CD91^f/fCD11c^cre mice. (g) Mice were immunized with low-dose (LD) or high-dose (HD) gp96 or given PBS. At 18 h post-immunization, lymph nodes were harvested and stained for CD91 in pDCs and cDCs. Shown are CD91 MFI values for each population. n=5/group, data are from one representative experiment of three independent experiments. Data are represented as mean±s.d. ns, not significant, *P<0.05 (Student's t-test used in c,d,e; one-way ANOVA used in a,b,g).